1. Generics Bulletin
  2. >>Products
  3. >>Generics

Remdesivir Rivals Hit Indian Market

Hetero And Cipla's Versions Launched, 'Surplus' Envisaged By August

 
• By Anju Ghangurde and Dave Wallace

Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.

Coins, money and COVID-19 on scale. Concepts of economics against coronavirus. Balancing and managing losses. 3D render
Hetero, Cipla Hit Market With Generic Remdesivir • Source: Shutterstock

There has been a flurry of activity around investigational COVID-19 treatments in India over the past week.

While Glenmark became the first Indian firm to get the go-ahead for its version of the oral antiviral favipiravir, news of much-anticipated regulatory clearances for local licensees of Gilead Sciences’ remdesivir, the injectable antiviral in the global spotlight, also trickled in soon after

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.